Cargando…
Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET
Purpose. To assess whether the differences in vascular-metabolic relationships between lymphoma masses and colorectal liver metastases predicted from previous histopathological studies can be demonstrated by dynamic contrast-enhanced CT (DCE-CT) combined with fluorodeoxyglucose positron emission tom...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094879/ https://www.ncbi.nlm.nih.gov/pubmed/21629862 http://dx.doi.org/10.1155/2011/679473 |
_version_ | 1782203605356380160 |
---|---|
author | Miles, K. A. Williams, R. E. Yu, D. Griffiths, M. R. |
author_facet | Miles, K. A. Williams, R. E. Yu, D. Griffiths, M. R. |
author_sort | Miles, K. A. |
collection | PubMed |
description | Purpose. To assess whether the differences in vascular-metabolic relationships between lymphoma masses and colorectal liver metastases predicted from previous histopathological studies can be demonstrated by dynamic contrast-enhanced CT (DCE-CT) combined with fluorodeoxyglucose positron emission tomography (FDG-PET). Methods. DCE-CT and FDG-PET studies were drawn from an imaging archive for patients with either lymphoma masses (n = 11) or hepatic metastases from colorectal cancer (CRM: n = 12). Tumour vascularity was assessed using DCE-CT measurements of perfusion. Tumour glucose metabolism was expressed as the mean FDG Standardised Uptake Value (SUV(FDG)). The relationship between metabolism and vascularity in each group was assessed from SUV(FDG) /perfusion ratios and Pearson correlation coefficients. Results. An SUV(FDG) threshold of 3.0 was used to designate lymphoma masses as active (AL, n = 6) or inactive lymphoma (IL, n = 5). Tumour perfusion was significantly higher in AL (0.65 mL/min/mL) than CRM (0.37 mL/min/mL: P = .031) despite similar SUV(FDG) (5.05 and 5.33, resp.). AL demonstrated higher perfusion values than IL (0.24 mL/min/mL: P = .006). SUV(FDG)/perfusion was significantly higher in CRM (15.3 min) than IL (4.2 min, P < .01). There was no correlation between SUV(FDG) and perfusion for any patient group. |
format | Text |
id | pubmed-3094879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30948792011-05-31 Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET Miles, K. A. Williams, R. E. Yu, D. Griffiths, M. R. Int J Mol Imaging Clinical Study Purpose. To assess whether the differences in vascular-metabolic relationships between lymphoma masses and colorectal liver metastases predicted from previous histopathological studies can be demonstrated by dynamic contrast-enhanced CT (DCE-CT) combined with fluorodeoxyglucose positron emission tomography (FDG-PET). Methods. DCE-CT and FDG-PET studies were drawn from an imaging archive for patients with either lymphoma masses (n = 11) or hepatic metastases from colorectal cancer (CRM: n = 12). Tumour vascularity was assessed using DCE-CT measurements of perfusion. Tumour glucose metabolism was expressed as the mean FDG Standardised Uptake Value (SUV(FDG)). The relationship between metabolism and vascularity in each group was assessed from SUV(FDG) /perfusion ratios and Pearson correlation coefficients. Results. An SUV(FDG) threshold of 3.0 was used to designate lymphoma masses as active (AL, n = 6) or inactive lymphoma (IL, n = 5). Tumour perfusion was significantly higher in AL (0.65 mL/min/mL) than CRM (0.37 mL/min/mL: P = .031) despite similar SUV(FDG) (5.05 and 5.33, resp.). AL demonstrated higher perfusion values than IL (0.24 mL/min/mL: P = .006). SUV(FDG)/perfusion was significantly higher in CRM (15.3 min) than IL (4.2 min, P < .01). There was no correlation between SUV(FDG) and perfusion for any patient group. Hindawi Publishing Corporation 2011 2011-04-26 /pmc/articles/PMC3094879/ /pubmed/21629862 http://dx.doi.org/10.1155/2011/679473 Text en Copyright © 2011 K. A. Miles et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Miles, K. A. Williams, R. E. Yu, D. Griffiths, M. R. Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET |
title | Demonstrating Intertumoural Differences in Vascular-Metabolic
Phenotype with Dynamic Contrast-Enhanced CT-PET |
title_full | Demonstrating Intertumoural Differences in Vascular-Metabolic
Phenotype with Dynamic Contrast-Enhanced CT-PET |
title_fullStr | Demonstrating Intertumoural Differences in Vascular-Metabolic
Phenotype with Dynamic Contrast-Enhanced CT-PET |
title_full_unstemmed | Demonstrating Intertumoural Differences in Vascular-Metabolic
Phenotype with Dynamic Contrast-Enhanced CT-PET |
title_short | Demonstrating Intertumoural Differences in Vascular-Metabolic
Phenotype with Dynamic Contrast-Enhanced CT-PET |
title_sort | demonstrating intertumoural differences in vascular-metabolic
phenotype with dynamic contrast-enhanced ct-pet |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094879/ https://www.ncbi.nlm.nih.gov/pubmed/21629862 http://dx.doi.org/10.1155/2011/679473 |
work_keys_str_mv | AT mileska demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet AT williamsre demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet AT yud demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet AT griffithsmr demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet |